Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 205 of 205 results for lymphoma

  1. Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]

    In development Reference number: GID-TA11909 Expected publication date: TBC

  2. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

  3. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  4. NICE real-world evidence framework (ECD9)

    This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  5. First-ever NHS treatment approved for advanced Hodgkin lymphoma

    New combination therapy offers hope to 800 people annually with late-stage blood cancer.

  6. Record number of positive recommendations for blood cancer treatments

    Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.

  7. Ground-breaking CAR-T therapy to treat aggressive form of blood cancer approved

    More than 400 people set to benefit after NICE recommends first personalised immunotherapy for lymphoma.

  8. First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK

    More than 700 people set to benefit from new treatment option for advanced lymphoma.

  9. Two new personalised immunotherapy treatments for aggressive forms of blood cancer recommended for the Cancer Drugs Fund

    NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer.

  10. Green light for groundbreaking personalised cancer therapy that reprogrammes immune system

    We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.